Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism



Status:Completed
Conditions:Endocrine
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:4/17/2018
Start Date:November 2013
End Date:September 2016

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The purpose of this study is to determine whether mifepristone is an effective treatment for
hyperglycemia due to mild hypercortisolism.

- To test the hypothesis that GR blockade with mifepristone will decrease the severity of
metabolic syndrome features as measured by waist circumference, lipid profile, body mass
index, blood pressure and insulin resistance, measured by HOMA-IR score.

- To test the hypothesis that GR blockade with mifepristone will improve QoL, depression
and anxiety scores, measured by validated assessments, in patients with mild
hypercortisolism.


Inclusion Criteria:

- >18 years of age

- Incidentally noted adrenal nodule <4 cm with benign imaging characteristics

- Evidence of mild hypercortisolism

- Evidence of diabetes or abnormal glucose tolerance

Exclusion Criteria:

- contraindication to mifepristone

- Indication for unilateral adrenalectomy

- Evidence of other adrenal hormone hypersecretion

- lactating mothers

- women of childbearing age unwilling to use an effective, nonhormonal form of
contraception
We found this trial at
1
site
Icahn School of Medicine at Mount Sinai
1428 Madison Ave
New York, New York 10029
(212) 241-6500
Principal Investigator: Alice C Levine, MD
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai is...
?
mi
from
New York, NY
Click here to add this to my saved trials